The Amyloid Beta A4 Protein pipeline drugs market research report outlays comprehensive information on the Amyloid Beta A4 Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Amyloid Beta A4 Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Metabolic Disorders, Infectious Disease, and Ophthalmology which include the indications Alzheimer’s Disease, Parkinson’s Disease, Type 2 Diabetes, Amyloidosis, Coronavirus Disease 2019 (COVID-19), Infectious Disease, Glaucoma, and Age Related Macular Degeneration. It also reviews key players involved in Amyloid Beta A4 Protein targeted therapeutics development with respective active and dormant or discontinued products.
The Amyloid Beta A4 Protein pipeline targets constitutes close to 121 molecules. Out of which, approximately 87 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 3, 4, 9, 16, 2, 42, and 11 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 25, and 9 molecule.
Amyloid Beta A4 Protein overview
Amyloid beta A4 protein (Aβ) is a small peptide of 39-43 amino acids that is produced from the amyloid precursor protein (APP). Aβ is a major component of amyloid plaques, which are neuropathological hallmarks of Alzheimer’s disease (AD). Aβ plaques are extracellular deposits that accumulate in the brain and are thought to contribute to the cognitive decline and dementia associated with AD.
For a complete picture of Amyloid Beta A4 Protein’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
